Showing results (121-130 of 3,351) with videos related to

Sort By:
Pageof 336
The Lancet. Oncology|July 3, 2004
Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonistsChristian Grommes, Gary E Landreth, Michael T Heneka
The Lancet. Oncology|July 3, 2004
Unanswered questions in acute myeloid leukaemiaFelicetto Ferrara
The Lancet. Oncology|January 14, 2022
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trialYoon-Koo Kang, Li-Tzong Chen, Min-Hee Ryu, et al.
The Lancet. Oncology|January 17, 2022
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trialQing Zhou, Ming Chen, Ou Jiang, et al.
The Lancet. Oncology|January 17, 2022
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trialCaicun Zhou, Ziping Wang, Yuping Sun, et al.
The Lancet. Oncology|December 2, 2021
Financial toxicity in cancer care in India: a systematic reviewJeffrey Mathew Boby, Senthil Rajappa, Aju Mathew
The Lancet. Oncology|December 2, 2021
Avoidance or adaptation of radiotherapy in patients with cancer with Li-Fraumeni and heritable TP53-related cancer syndromesJuliette Thariat, Francois Chevalier, Daniel Orbach, et al.
The Lancet. Oncology|September 2, 2022
The QT interval prolongation potential of anticancer and supportive drugs: a comprehensive overviewEline L Giraud, Kaylee R M Ferrier, Nienke A G Lankheet, et al.
The Lancet. Oncology|December 13, 2021
Common genetic variation in alcohol-related hepatocellular carcinoma: a case-control genome-wide association studyEric Trépo, Stefano Caruso, Jie Yang, et al.
The Lancet. Oncology|November 18, 2021
177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trialJonathan R Strosberg, Martyn E Caplin, Pamela L Kunz, et al.
Pageof 336